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Abstract
The annexins are a family of highly homologous phospholipid binding proteins, which share a four-domain structure, with
one member of the family ^ annexin VI ^ having a duplication consisting of eight domains. Thus far, ten annexins have been
described in mammals. Although the biological functions of the annexins have not been definitively established, two human
diseases involving annexin abnormalities (‘annexinopathies’) have been identified as of the time of writing. Overexpression of
annexin II occurs in the leukocytes of a subset of patients having a hemorrhagic form of acute promyelocytic leukemia.
Underexpression of annexin V occurs on placental trophoblasts in the antiphospholipid syndrome and in preeclampsia. Also,
an animal model has been described in which annexin VII is underexpressed and is associated with disease, but the relevance
of this animal model to human disease is not yet understood. Future research is likely to elucidate additional
‘annexinopathies’. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Overview of annexins
The annexins (for extensive review see [1]) are a
family of phospholipid binding proteins that were
originally isolated by various investigators from var-
ious tissues and assigned their previous names based
upon their tissue of origin or on their presumed func-
tions. With amino acid and nucleotide sequencing
came the recognition of identities among several in-
dependently isolated annexins, their structural rela-
tionships and di¡erences, and their shared properties
of binding calcium and phospholipids. Thus far, sev-
eral hundred di¡erent annexins, including ten in
mammals (I^VIII, XI and XIII), have been de-
scribed. The remainder have been described in Dro-
sophila, Hydra, protozoa and a wide range of plants
[2]. Their ‘canonical structure’ is composed of repet-
itive homologous domains consisting of sequences of
about 70 amino acids, with most of the annexins
having four of these domains. The amino-terminal
tails of the various annexins are unique and are be-
lieved to confer the functional speci¢cities.
While their structural homology and the shared
attributes of binding to calcium and to phospholipid
suggest the possibility of common functional themes,
these have remained elusive. Roles in physiology and
human disease have recently been proposed for some
of these proteins.
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2. Annexin II and acute promyelocytic leukemia
Annexin II has been proposed to play a role in the
process of ¢brin clot dissolution. The protein pro-
motes ¢brinolysis on the apical surfaces of vascular
endothelial cells by serving as a platform for the
binding of plasminogen and tissue plasminogen acti-
vator [3]. This permits the e⁄cient cleavage of plas-
minogen by tissue plasminogen activator to produce
the ¢brinolytic enzyme, plasmin.
It has been known for some time that subsets of
patients with acute promyelocytic leukemia are prone
to develop a severe bleeding disorder [4]. Among the
hallmarks of this disorder are hypo¢brinogenemia
and excessive ¢brin(ogen)olysis for which the patho-
physiology has not been previously understood. This
condition had been previously attributed to dissemi-
nated intravascular coagulation [4]. Recently, over-
expression of annexin II has been described in one
such subset of patients with acute promyelocytic leu-
kemia [5]. Annexin II is abnormally elevated in pa-
tients having the 15:17 translocation form of acute
promyelocytic leukemia and is associated with exces-
sive ¢brinolysis. This proposed mechanism (illus-
trated in Fig. 1) is supported by the ¢nding that
leukemia cell-mediated ¢brinolysis was inhibited
with polyclonal anti-annexin II antibodies. Also, ¢-
brinolysis could be increased in a non-¢brinolytic
acute promyelocytic leukemia cell line by inducing
the expression of annexin II [5]. At this point, no
other diseases of annexin II overexpression have yet
been identi¢ed. There have not yet been described
any clinical annexin II de¢ciency states.
3. Annexin V and the antiphospholipid syndrome
The antiphospholipid (aPL) syndrome is an auto-
immune condition that occurs in patients having
antibodies against anionic phospholipid-protein com-
Fig. 1. Proposed mechanism of hemorrhage in acute promyelocytic leukemia. Plasmin is formed on assembly of plasminogen and tis-
sue plasminogen activator (t-PA) on cell surface-associated annexin II (A). At the cell surface, plasmin is protected from its primary
inhibitor, K2-plasmin inhibitor (K2-PI), which is produced in the liver. Once released, plasmin rapidly forms an irreversible, inactive
complex with K2-PI. Plasmin is generated on the surface of endothelial cells and, to a lesser extent, on other cells. In leukemias other
than acute promyelocytic leukemia, released plasmin is neutralized by K2-PI, and the plasmin-K2-PI complexes are cleared in the liver.
In acute promyelocytic leukemia, plasmin is generated at an abnormally high rate because of overexpression of annexin II on the leu-
kemic cells (B). As a result, K2-PI is consumed, and active plasmin accumulates in the plasma. The unopposed ¢brinolytic activity of
plasmin causes a hemorrhagic disorder. (Reprinted with permission from The New England Journal of Medicine [4].)
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plexes. The syndrome manifests as vascular throm-
boembolism or recurrent pregnancy losses. For re-
cent comprehensive reviews the reader is referred to
[6,7]. The disorder is classi¢ed as ‘primary’ in the
absence of another autoimmune condition, such as
systemic lupus erythematosus, and ‘secondary’ in the
presence of such disorders.
aPL antibodies are identi¢ed by their reactivity to
anionic phospholipids (or protein-phospholipid com-
plexes) in solid phase immunoassays and by their
inhibition of phospholipid-dependent coagulation re-
actions (the ‘lupus anticoagulant’ e¡ect). The patho-
physiologic mechanism(s) of this syndrome have
been confusing because of the apparent multiplicity
of antigenic determinants recognized by the antibod-
ies and the uncertainty about whether any of these
speci¢cities are causally relevant to the disease pro-
cess. While a large number of e¡ects have been de-
scribed for the antibodies in vitro and in cell culture
systems [6], aPL antibody-mediated disruption of an-
nexin V binding to phospholipid o¡ers a particularly
intriguing mechanism.
Annexin V has potent anticoagulant properties in
vitro and signi¢cantly prolongs the phospholipid-de-
Fig. 2. Model for mechanisms of the ‘lupus anticoagulant e¡ect’ and the inhibition of annexin V and acceleration of coagulation by
antiphospholipid antibodies. (A) Anionic phospholipids (negative charges), when exposed on the apical surface of the cell membrane
bilayer, serve as potent cofactors for the assembly of three di¡erent coagulation complexes: the tissue factor (TF)-VIIa complex, the
IXa-VIIIa complex and the Xa-Va complex, and thereby accelerating blood coagulation. The TF complexes yield either factor IXa or
factor Xa, the IXa complex yields factor Xa, and the Xa formed from both of these reactions is the active enzyme in the prothrombi-
nase complex which yields factor IIa (thrombin), which in turn cleaves ¢brinogen to form ¢brin. (B) Annexin V, in the absence of
antiphospholipid antibodies, forms clusters which bind with high a⁄nity to the anionic phospholipid surface and shield the surface
from the assembly of the phospholipid-dependent coagulation complexes, thereby inhibiting coagulation reactions. (C) In the absence
of annexin V, antiphospholipid antibodies can prolong the coagulation times, compared to control antibodies, by reducing the access
of coagulation factors to anionic phospholipids. This may result in a ‘lupus anticoagulant e¡ect’. (D) In the presence of annexin V,
antiphospholipid antibodies, either directly or via interaction with protein-phospholipid cofactors, disrupt the ability of annexin V to
cluster on the phospholipid surface, resulting in a net increase of the amount of anionic phospholipid available for promoting coagula-
tion reactions. This manifests in the net acceleration of coagulation in vitro and in thrombophilia in vivo. (Reprinted with permission
from Blood [18].)
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pendent coagulation reactions. The anticoagulant ef-
fect is due to the ability of this protein to displace
coagulation proteins from phospholipid surfaces [8].
Interestingly, there is evidence that annexin V forms
clusters on exposed phospholipid [8] in the form of
two-dimensional crystalline arrays [9,10]. This shield
of annexin V on the phospholipid surface blocks
these phospholipids from availability for any coagu-
lation reactions and also reduces the lateral mobility
of any reactants that are already bound to the phos-
pholipid membrane.
Annexin V is necessary for the maintenance of
placental integrity [11] ; infusion of pregnant mice
with polyclonal anti-annexin V antibodies resulted
in placental infarction and pregnancy wastage. The
protein is expressed in an apparently constitutive
manner by human placental trophoblasts and has
been immunolocalized to the apical surfaces of the
syncytiotrophoblasts lining the placental villi [12],
where it is densely expressed. Here, the protein is
present at the interface between the maternal blood
which circulates through the intervillous space and
the fetal trophoblasts. De¢ciency of annexin V has
been described in placentas of patients with the anti-
phospholipid syndrome [13].
Recently, it was reported that annexin V expres-
sion is decreased on trophoblasts of preeclamptic
placentas and that the degree of the decrease corre-
lated with elevation of markers for activation of
blood coagulation [14]. Also, annexin V is reduced
on placental villi [15] and on cultured placental
trophoblasts exposed to IgG fractions from aPL pa-
tients [16], and by a monoclonal antiphosphatidylser-
ine antibody [17]. This antibody-mediated reduction
of annexin V is associated with acceleration of plas-
ma coagulation [16,18] and increased binding of pro-
thrombin [17], and can occur on non-cellular phos-
pholipid surfaces [18,19]. The mechanism for aPL
antibody-mediated acceleration of coagulation is il-
lustrated in Fig. 2.
Taken together, the available data support the hy-
pothesis that annexin V has a thrombomodulatory
function on the surfaces which line the placental
and systemic vasculatures. Reduction of annexin V
in preeclampsia and in the aPL syndrome is associ-
ated with pregnancy complications and losses.
4. Annexin VII knockout mice
The annexin VII gene has been knocked out and
the nullizygous annexin VII (3/3) phenotype has
been found to be lethal at embryonic day 10 because
of cerebral hemorrhage [20]. The heterozygous an-
nexin VII (+/3) mouse, although expressing only
low levels of annexin VII protein, is viable. That
phenotype is associated with a substantial defect in
insulin secretion, although the insulin content of the
islets is 8^10-fold higher in the mutants than in the
normal littermate control. This appears to be due
to a change in the ability of inositol 1,4,5-trisphos-
phate (IP(3))-generating agonists to release intracel-
lular calcium. The major molecular consequence of
lower annexin VII expression appears to be the pro-
found reduction in IP(3) receptor expression and
function in pancreatic islets [20]. The relevance of
these ¢ndings to human disease has not yet been
established.
5. Summary and conclusions
We now have signi¢cant evidence that two of the
annexins, II and V, play roles in the physiologic con-
trol of blood coagulation reactions and also that
abnormalities of the expression of these proteins
are associated with clinical disease. Annexin II is
overexpressed on leukocytes in patients with acute
promyelocytic leukemia having the 15:17 transloca-
tion, which correlates with increased ¢brinolysis and
bleeding. Annexin V is decreased on placental tropho-
blasts and on endothelial cells in the antiphospholi-
pid syndrome, an antibody-mediated e¡ect which is
associated with pregnancy losses and with thrombo-
sis. In animal models, knockout of another annexin
has been associated with disease. De¢ciency of an-
nexin VII has been associated with decreased insulin
release and alterations in the morphology of pancre-
atic islets. These abnormalities have not yet been
related to human diseases.
We may anticipate that forthcoming research will
reveal additional ‘annexinopathies’ which will in-
clude a broad range of genetic and acquired abnor-
malities of the human annexins.
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